Tag: serotonin

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
December 4, 2012
Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…
READ MORE
Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment
April 2, 2012
Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA). LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…
READ MORE
Carcinoid Heart Disease: Facts You Need to Know
December 17, 2009
“Serotonin seems to be the single most damaging substance in carcinoid heart disease,” explains JEROME S. ZACKS, MD. Dr. Zacks, a cardiologist, is a member of the Carcinoid/ Neuroendocrine Tumor Center at Mount Sinai School of Medicine in New York City,… READ MORE